Recurrent neonatal seizures result in long-term increases in neuronal network excitability in the rat neocortex.
Neonatal seizures are associated with a high likelihood of adverse neurological outcomes, including mental retardation, behavioral disorders, and epilepsy. Early seizures typically involve the neocortex, and post-neonatal epilepsy is often of neocortical origin. However, our understanding of the consequences of neonatal seizures for neocortical function is limited. In the present study, we show that neonatal seizures induced by flurothyl result in markedly enhanced susceptibility of the neocortex to seizure-like activity. This change occurs in young rats studied weeks after the last induced seizure and in adult rats studied months after the initial seizures. Neonatal seizures resulted in reductions in the amplitude of spontaneous inhibitory postsynaptic currents and the frequency of miniature inhibitory postsynaptic currents, and significant increases in the amplitude and frequency of spontaneous excitatory postsynaptic currents (sEPSCs) and in the frequency of miniature excitatory postsynaptic currents (mEPSCs) in pyramidal cells of layer 2/3 of the somatosensory cortex. The selective N-methyl-D-aspartate (NMDA) receptor antagonist D-2-amino-5-phosphonovalerate eliminated the differences in amplitude and frequency of sEPSCs and mEPSCs in the control and flurothyl groups, suggesting that NMDA receptors contribute significantly to the enhanced excitability seen in slices from rats that experienced recurrent neonatal seizures. Taken together, our results suggest that recurrent seizures in infancy result in a persistent enhancement of neocortical excitability.
Isaeva
Elena
E
Department of Neurology, Neuroscience Center at Dartmouth, Dartmouth Medical School, Lebanon, NH 03756, USA. olena.isaeva@gmail.com
Isaev
Dmytro
D
Savrasova
Alina
A
Khazipov
Rustem
R
Holmes
Gregory L
GL
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000375:Aging; D000818:Animals; D000831:Animals, Newborn; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects; D019579:Neocortex / Q000187:drug effects / Q000503:physiopathology*; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D017966:Pyramidal Cells / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism; D012008:Recurrence; D012640:Seizures / Q000139:chemically induced / Q000150:complications* / Q000503:physiopathology*; D013003:Somatosensory Cortex / Q000187:drug effects / Q000503:physiopathology; D013997:Time Factors
D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D015763:2-Amino-5-phosphonovalerate
J Neurochem. 2004 Jan;88(1):91-101
14675153
J Neurosci. 1996 Jul 1;16(13):4283-92
8753889
Curr Opin Neurol. 2001 Apr;14(2):187-92
11262734
Ann Neurol. 1998 Dec;44(6):845-57
9851428
Ann Neurol. 2003 Dec;54(6):706-18
14681880
Brain Res Dev Brain Res. 2004 Sep 17;152(2):137-42
15351501
Epilepsia. 1987 Sep-Oct;28(5):537-41
3653058
J Neurophysiol. 2001 Dec;86(6):2887-95
11731545
J Neurophysiol. 1997 Apr;77(4):1924-38
9114245
Neuron. 1997 Feb;18(2):243-55
9052795
Ann Neurol. 2007 May;61(5):411-26
17323345
Eur J Neurosci. 2006 Mar;23(6):1559-66
16553619
J Neurophysiol. 2000 Jan;83(1):315-21
10634874
Epilepsy Res. 2009 Dec;87(2-3):286-9
19828295
Neurosci Lett. 2004 Sep 30;368(3):254-7
15364406
Neuron. 2003 Jan 23;37(2):299-309
12546824
Acta Neurol Scand. 1992 Feb;85(2):128-31
1574986
Ment Retard Dev Disabil Res Rev. 2000;6(4):229-41
11107188
Ann Neurol. 2000 Jun;47(6):729-38
10852538
Prog Neurobiol. 2004 May;73(1):1-60
15193778
Neuroscience. 1996 Nov;75(2):339-44
8931000
Eur J Pediatr. 1995 Jun;154(6):499-500
7671952
J Neuropathol Exp Neurol. 1998 Jun;57(6):615-34
9630240
J Pharmacol Exp Ther. 2004 Sep;310(3):871-80
15084648
J Neurophysiol. 2009 May;101(5):2290-6
19261712
Brain Res Dev Brain Res. 2002 Apr 30;135(1-2):101-4
11978398
Brain Res Dev Brain Res. 1999 Dec 10;118(1-2):99-107
10611508
Brain Res Dev Brain Res. 1996 Sep 2;95(2):283-92
8874904
J Neurophysiol. 1997 Apr;77(4):2139-52
9114261
J Neurosci. 2001 Oct 15;21(20):8154-63
11588188
J Neurosci. 2000 Dec 1;20(23):8822-30
11102490
Neurology. 2007 Nov 6;69(19):1816-22
17984448
Epilepsy Res. 2009 Aug;85(2-3):221-30
19395239
J Neurosci. 2005 Jun 8;25(23):5511-20
15944379
J Neurophysiol. 2001 Oct;86(4):1644-51
11600627
Pediatr Neurol. 2003 Apr;28(4):277-80
12849880
J Physiol. 2004 Jun 15;557(Pt 3):829-41
15090604
J Neurosci. 2006 Jan 11;26(2):406-10
16407536
Epilepsia. 1996;37 Suppl 1:S26-40
8647050
J Pediatr. 2009 Sep;155(3):318-23
19540512
J Pediatr. 2002 Jun;140(6):707-12
12072874
Epilepsia. 1988 May-Jun;29(3):256-61
3371282
Neurology. 2000 Aug 22;55(4):506-13
10953181
Epilepsia. 1999;40 Suppl 1:S42-50; discussion S64-6
10421560
Neurology. 1997 Jan;48(1):189-96
9008517
Exp Neurol. 2009 Jun;217(2):378-87
19345685
Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):73-83
11718838
Lancet Neurol. 2003 Jan;2(1):33-42
12849299
J Neurophysiol. 2008 Aug;100(2):620-8
18497363
J Neurosci. 2005 Mar 30;25(13):3442-51
15800199
Arch Neurol. 2001 Aug;58(8):1264-8
11493167
Pediatrics. 1991 Sep;88(3):583-96
1881741
Epilepsia. 2005 Mar;46(3):356-66
15730532
J Physiol. 1995 Aug 1;486 ( Pt 3):723-34
7473233